Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Accumulated Expenses (2022 - 2025)

Oramed Pharmaceuticals' Accumulated Expenses history spans 4 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses changed N/A year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, changed N/A, while the annual FY2025 figure was $1.1 million, N/A changed from the prior year.
  • Accumulated Expenses reached $1.1 million in Q4 2025 per ORMP's latest filing, up from $233000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.1 million in Q4 2025 to a low of $21000.0 in Q4 2022.
  • Average Accumulated Expenses over 4 years is $268272.7, with a median of $29000.0 recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: increased 7.41% in 2024, then surged 2800.0% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $21000.0 in 2022, then skyrocketed by 2057.14% to $453000.0 in 2023, then tumbled by 93.6% to $29000.0 in 2024, then soared by 3637.93% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Accumulated Expenses are $1.1 million (Q4 2025), $233000.0 (Q3 2025), and $841000.0 (Q2 2025).